Inspirna
New York
About Inspirna
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs are first-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2)
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $144.6M
- Funding stage: Late Stage Venture
- Last round: Series D (Jul 2022)
- Website: inspirna.com
- Phone: (646) 856-9261
Industries & Categories
Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inspirna-85233 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.